wtx-124
·Code: WTX-124
wtx-124: sourced relationships with 1 company · 1 clinical trial tracked.
wtx-124 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect wtx-124 to HOWL; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could wtx-124 → HOWL affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Metastatic Solid TumorAdvanced Solid Tumor
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Werewolf Therapeutics, Inc. (HOWL) Metastatic Solid Tumor | Phase 1 |
Clinical Trial Registry Records (1)
A Multicenter Phase I/Ib Dose Escalation and Expansion Study of WTX-124 as Monotherapy and in Combination With Pembrolizumab in Patients With Selected Advanced or Metastatic Solid Tumors
Primary endpoint: Incidence of Dose Limiting Toxicities (DLTs) in monotherapy and combination therapy
Interventionalopen156 enrolledStarted 2022-08Completion 2026-0414 sites · United StatesWerewolf Therapeutics, Inc.
Frequently asked questions
Which companies have sourced relationships with wtx-124?
wtx-124 has dated SEC/FDA relationship records for Werewolf Therapeutics, Inc..
How many clinical trials involve wtx-124?
BioSniper tracks 1 clinical trial involving wtx-124.